According to industry sources on the 24th, companies including Yoo-Yu 制药, Hanall Biopharma, HLB Therapeutics, RudaCure, and PNP Biopharm have entered the race to develop 干眼症治疗药s.
Dry eye disease is known to have a very rigorous clinical process and approval criteria. Because it is a condition highly sensitive to environmental factors, it involves more variables than other 临床试验, and it is also difficult to objectively quantify drug 疗效 based on patients' subjective responses.
Nevertheless, no domestic company has ever succeeded in developing a new drug for this condition, and with the global 干眼症治疗药 market projected to expand to KRW 12 trillion by 2028, active research is underway.
Bioventure RudaCure is developing 干眼症治疗药 candidate 'RCI001.' According to RudaCure, RCI001 is expected to demonstrate faster 泪液分泎 疗效 and 角膜损伤恢复 compared to commercially available competing drugs, along with superior 滴眼顺应性 and safety. The company anticipates that the drug will show rapid onset of action while significantly reducing 副作用 such as 眼内压升高.